Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
Status:
Completed
Trial end date:
2021-05-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of a novel combination of
agents, enzalutamide and everolimus, for the treatment of patients with metastatic
castrate-resistant prostate cancer who have never received prior chemotherapy, or who have
previously received docetaxel chemotherapy and have progressive disease.